These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36780781)

  • 1. Serum neurofilament light chain in LRRK2 related Parkinson's disease: A five years follow-up.
    Nabizadeh F; Mohamadzadeh O; Hosseini H; Rasouli K; Afyouni NE
    J Clin Neurosci; 2023 Apr; 110():12-18. PubMed ID: 36780781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurofilament light chain as a mediator between LRRK2 mutation and dementia in Parkinson's disease.
    Yang D; Xie H; Wu S; Ying C; Chen Y; Ge Y; Yao R; Li K; Jiang Z; Chen G
    NPJ Parkinsons Dis; 2023 Sep; 9(1):132. PubMed ID: 37699957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
    Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
    J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer outcomes among Parkinson's disease patients with leucine rich repeat kinase 2 mutations, idiopathic Parkinson's disease patients, and nonaffected controls.
    Agalliu I; Ortega RA; Luciano MS; Mirelman A; Pont-Sunyer C; Brockmann K; Vilas D; Tolosa E; Berg D; Warø B; Glickman A; Raymond D; Inzelberg R; Ruiz-Martinez J; Mondragon E; Friedman E; Hassin-Baer S; Alcalay RN; Mejia-Santana H; Aasly J; Foroud T; Marder K; Giladi N; Bressman S; Saunders-Pullman R
    Mov Disord; 2019 Sep; 34(9):1392-1398. PubMed ID: 31348549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased basal forebrain volumes could prevent cognitive decline in LRRK2 Parkinson's disease.
    Batzu L; Urso D; Grothe MJ; Veréb D; Chaudhuri KR; Pereira JB
    Neurobiol Dis; 2023 Jul; 183():106182. PubMed ID: 37286171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression in the LRRK2-Asssociated Parkinson Disease Population.
    Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
    JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofilament light predicts worse nonmotor symptoms and depression in Parkinson's disease.
    Urso D; Batzu L; Logroscino G; Ray Chaudhuri K; Pereira JB
    Neurobiol Dis; 2023 Sep; 185():106237. PubMed ID: 37499883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
    Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
    J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
    Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
    J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
    Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mild cognitive impairment among LRRK2 and GBA1 patients with Parkinson's disease.
    Thaler A; Livne V; Rubinstein E; Omer N; Faust-Socher A; Cohen B; Giladi N; Shirvan JC; Cedarbaum JM; Gana-Weisz M; Goldstein O; Orr-Urtreger A; Alcalay RN; Mirelman A
    Parkinsonism Relat Disord; 2024 Jun; 123():106970. PubMed ID: 38691978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
    Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.
    Cao M; Gu ZQ; Li Y; Zhang H; Dan XJ; Cen SS; Li DW; Chan P
    Neurosci Bull; 2016 Dec; 32(6):572-576. PubMed ID: 27699718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accumulation of mitochondrial 7S DNA in idiopathic and LRRK2 associated Parkinson's disease.
    Podlesniy P; Puigròs M; Serra N; Fernández-Santiago R; Ezquerra M; Tolosa E; Trullas R
    EBioMedicine; 2019 Oct; 48():554-567. PubMed ID: 31631040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
    Vissers MFJM; Troyer MD; Thijssen E; Pereira DR; Heuberger JAAC; Groeneveld GJ; Huntwork-Rodriguez S
    Clin Transl Sci; 2023 Aug; 16(8):1408-1420. PubMed ID: 37177855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease.
    Gaig C; Vilas D; Infante J; Sierra M; García-Gorostiaga I; Buongiorno M; Ezquerra M; Martí MJ; Valldeoriola F; Aguilar M; Calopa M; Hernandez-Vara J; Tolosa E
    PLoS One; 2014; 9(10):e108982. PubMed ID: 25330404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson's disease.
    Ng ASL; Tan YJ; Yong ACW; Saffari SE; Lu Z; Ng EY; Ng SYE; Chia NSY; Choi X; Heng D; Neo S; Xu Z; Keong NCH; Tay KY; Au WL; Tan LCS; Tan EK
    Mol Neurodegener; 2020 Jun; 15(1):33. PubMed ID: 32503574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.
    Braunger LJ; Knab F; Gasser T
    J Parkinsons Dis; 2024; 14(5):977-991. PubMed ID: 38848197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.